Funding and Investments

Sep 10, 2018
By BioPharm International Editors
The collaboration will explore the potential of Dyadic’s gene-expression platform to produce multiple biologic vaccines and drugs.
Jul 27, 2018
By BioPharm International Editors
The National Science Foundation grant will be used to commercialize a synthetic biology platform for cancer drug development.
Jul 03, 2018
By BioPharm International Editors
The pharma major intends to spinoff Alcon as a stand-alone eye-care devices company.
Jul 03, 2018
By BioPharm International Editors
Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.
Jun 22, 2018
By BioPharm International Editors
The three-year collaboration will focus on developing vaccines for up to five infectious disease pathogens.
Jun 22, 2018
By BioPharm International Editors
The company has completed the first phase of expansion at its headquarters in Freiburg, Germany, in anticipation of increasing demand as cell and gene therapies approach commercialization.
Jun 07, 2018
By BioPharm International Editors
A new report released at the BIO International Convention shows that the US bioscience industry has had a $2-trillion economic impact and has accelerated venture capital investment and job growth.
May 31, 2018
By BioPharm International Editors
Ingenza, in partnership with the University of Dundee and Drochaid Research Services, will work on a project to recycle CO2 emissions from bioprocessing plants to serve as feedstock and energy inputs.
May 25, 2018
By BioPharm International Editors
The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.
May 17, 2018
By BioPharm International Editors
Internationalization and regulatory reform are driving growth and investment China.
native1_300x100
lorem ipsum